<DOC>
	<DOC>NCT01823965</DOC>
	<brief_summary>In the prospective monocentric open label trial patients with diabetic macular edema will be treated with intravitreal injections of ranibizumab given for 3 months then with laser grid at month 4. During follow-up a ranibizumab injection will be performed every 2 months in case of best-corrected visual acuity decreased more than 5 letters.</brief_summary>
	<brief_title>Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>diabetes mellitus (1 or2) decreased vision from Diabetic Macular Edema (study eye Best Corrected Visual Acuity&lt;69 letters using E.T.D.R.S testing) macular edema history of severe cardiac disease stroke within 12 months intraocular inflammation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>